The FDA has approved a new colorectal cancer blood test by Guardant Health called Shield, making it the first test of its kind to meet requirements for Medicare coverage. The Shield test detects “free-floating” fragments of cancer DNA in the bloodstream, offering a noninvasive and convenient alternative to traditional colorectal cancer (CRC) screenings.
Accuracy and Accessibility
The ECLIPSE clinical trial, which led to FDA approval, found that Shield accurately confirmed 83.1% of colorectal cancer cases. While this blood test provides greater accessibility, it comes with a reduction in accuracy compared to traditional methods. Shield is particularly significant given that fewer than 60% of adults aged 45 to 75 in the United States undergo colorectal cancer screening, despite it being the second-leading cause of cancer-related deaths. Early detection of colorectal cancer is crucial for effective treatment.
Medical Community’s Perspective
Dr. Daniel Chung, a gastroenterologist at Massachusetts General Hospital, emphasizes that the approval of the Shield blood test represents a major advancement in making screening more accessible. However, medical professionals caution that the Shield test should not replace colonoscopy. Dr. Ben Park of the Vanderbilt-Ingram Cancer Center highlights the potential risk of missed diagnoses, noting that negative results from the Shield test are not always reliable.
Dr. Christopher Chen of the Stanford Cancer Institute underscores that colonoscopy remains the gold standard for CRC screening. Similarly, Dr. Uri Ladabaum from Stanford Medicine warns that substituting Shield for traditional screening methods in patients willing to undergo those tests could worsen outcomes. Nonetheless, the Shield test could benefit those unable or unwilling to have a colonoscopy.
Trial Results and Limitations
The ECLIPSE trial, which included nearly 8,000 participants aged 45 to 84, demonstrated that Shield identified colorectal cancer in 83.1% of cases confirmed by colonoscopy. However, it also showed a 16.9% false-negative rate, which is concerning given the high incidence of colorectal cancer diagnoses annually. Additionally, the Shield test only detects pre-cancerous lesions in about 13% of cases, limiting its role as a preventive screen.
Conclusion
Guardant Health’s Shield blood test offers a new opportunity to increase CRC screening adherence, particularly for those reluctant to undergo traditional methods. While it is a significant step forward, medical professionals agree that it should be used as an adjunct to, not a replacement for, colonoscopy. The FDA approval of Shield for Medicare coverage expands its availability, potentially improving early detection and treatment outcomes for colorectal cancer.
Our Mission
We are dedicated to help you maintain your healthy life. Our mission is to provide the highest quality and affordable health care to you and your family.Your health isn’t just some numbers and figures. A person’s well been lays upon a healthy body, good physical condition and more importantly, a sense of feeling well.
Locations:
3916 Prince St STE 251, Flushing, NY 11354
43-73 Union St Suite 1B, Flushing, NY 11355
Disclaimer: The content on this blog is provided for general informational purposes only and is not intended as, nor should it be considered a substitute for, professional medical advice, diagnosis, or treatment. The information provided is meant to be a helpful starting point for your own research and should not be solely relied upon to make decisions about your health or the health of others. The author of this blog makes no representation or warranty of any kind, express or implied, regarding the accuracy, adequacy, validity, reliability, availability, or completeness of any information presented on this site. Under no circ*mstances should the author be held liable for any errors, omissions, or inaccuracies in the content or for any actions taken in reliance thereon. Always consult with a qualified healthcare professional before making any changes to your diet, medication, exercise routine, or lifestyle, or when seeking advice regarding a specific medical condition or health concern. The use or reliance of any information contained on this site is solely at your own risk. This blog may contain links to external websites that are not affiliated with the author. The author is not responsible for and does not endorse the content of such external sites. Any references to products, services, or health care providers on this website are not an endorsem*nt or recommendation by the author. By using this blog, you agree to indemnify and hold harmless the author, their agents, and affiliates from and against any and all claims, liabilities, damages, losses, or expenses, including legal fees and costs, arising out of or in any way connected with your access to or use of this blog.
